Ovasave for Treating Refractory Crohn’s Disease
July 15, 2016 | Technology Forecasts
Note: The following ratings and comments reflect the opinions and consensus of an expert panel convened by ECRI Institute to review information on this topic.
Anticipated Utilization: 2(Expected to be used by 20% to 40% of patients with anticipated indications)
Ovasave® (TxCell SA, Valbonne, France) could offer a welcome option for some patients with refractory Crohn's disease (CD) who have exhausted conventional therapies. The manufacturer estimates that more than 100,000 people in Europe and the United States might be eligible for Ovasave each year. Available medications to treat CD include immunosuppressive therapy and biologics (TNF-inhibitors), which often have limited efficacy and tolerability issues. Although a high unmet need exists for new treatments for refractory CD, the high potential cost of the cell-based immunotherapy, frequency of injections, and lack of long-term efficacy data could temper utilization.
Estimated Adoption Status: 1(Early...